期刊文献+

2010年中国CHINET临床分离自无菌体液的细菌分布和耐药性监测 被引量:9

CHINET 2010 surveillance of bacterial distribution and resistance in sterile body fluids
下载PDF
导出
摘要 目的了解国内不同地区14所教学医院2010年从临床分离自脑脊液及其他无菌体液(胸水、腹水、胆汁等)的细菌分布和对抗菌药物的耐药性。方法共收集2010年临床分离的无菌体液2409株非重复的细菌,采用纸片扩散法进行药敏试验,结果按CLSI 2010年版标准判读药敏结果,采用WHONET 5.4软件进行数据分析。结果 2409株非重复的细菌中,革兰阴性菌1 353株,占56.2%,革兰阳性菌1 056株,占43.8%。脑脊液中最常见的细菌分别为:凝固酶阴性葡萄球菌(CNS)、鲍曼不动杆菌、肺炎克雷伯菌、金葡菌和大肠埃希菌。其他无菌体液中最常见的细菌分别为:大肠埃希菌、CNS、屎肠球菌、肺炎克雷伯菌和铜绿假单胞菌。脑脊液标本中MRSA和MRCNS的检出率分别为78.6%和69.7%。其他无菌体液标本中MRSA和MRCNS的检出率分别为60.3%和67.2%。未发现对万古霉素、替考拉宁和利奈唑胺耐药的葡萄球菌。脑脊液标本中未发现对万古霉素耐药的肠球菌属细菌,在其他无菌体液中发现17株对万古霉素耐药的屎肠球菌。脑脊液标本中产ESBLs大肠埃希菌和克雷伯菌属细菌(肺炎克雷伯菌和产酸克雷伯菌)的检出率分别为62.5%和30.0%,其他无菌体液标本中产ESBLs大肠埃希菌和克雷伯菌属细菌(肺炎克雷伯菌和产酸克雷伯菌)的检出率分别为50.4%和27.3%。脑脊液标本中泛耐药鲍曼不动杆菌、肺炎克雷伯菌和铜绿假单胞菌分别检出10株(18.2%)、8株(27.6%)和1株(7.7%)。其他无菌体液标本中泛耐药鲍曼不动杆菌、肺炎克雷伯菌、铜绿假单胞菌和大肠埃希菌分别检出43株(36.8%)、18株(11.5%)、3株(2.1%)和1株(0.2%)。结论脑脊液和其他无菌体液中主要病原菌是大肠埃希菌、CNS、屎肠球菌、肺炎克雷伯菌,鲍曼不动杆菌和铜绿假单胞菌。应防范泛耐药肠杆菌科细菌、铜绿假单胞菌和鲍曼不动杆菌对临床治疗造成严重威胁。 Objective To investigate the distribution and an- timicrobial resistance of the bacteria isolated from cerebrospi- nal fluid and other sterile body fluids from hospitals in sever- al regions of China. Methods Twelve general hospitals and two childrents hospitals were invclved in this program. Discdiffusion test (Kirby-Bauer method), E-test and MIC determination were employed to study the antimicrobial resistance. The data were analyzed by WHONET 5.4 software according to CLSI 2010 breakpoints. Results A total of 2 409 nonduplicate clini- cal isolates were collected from January to December in 2010, of which gram negative organisms and gram positive cocci accoun- ted for 56.2% (1 353/2 409) and 43.8% (1 056/2 409), respectively. Coagulase-negative Staphylococcus (CNS), B. bau- mannii, K. pneumoniae, S. aureus and E. coli were the most common bacterial species in cerebrospinal fluid. E. coli, CNS, E. faecium, K. pneumoniae and P. aeruginosa were the most frequently isolated species from other sterile body fluids. About 78.6% and 69.7% of the S. aureus and CNS isolates from cerebrospinal fluid were methicillin resistant, respectively, while 60.3G and 67.2% of the S. aureus and CNS strains from other sterile body fluids were methicillin resistant, respectively. No staphylococcal strain was found resistant to vancomycin, teicoplanin or linezolid. None of the enterococcal strains from cerebro- spinal fluid was resistant to vancomycin. A total of 17 E. faecium strains from other sterile body fluid were found resistant to vancomycin. ESBLs-producing strains accounted for 62.5% and 30.0~//00 in the E. coli and Klebsiella (K. pneumoniae, K. oacytoca) isolates from cerebrospinal fluid, respectively. About 50.4% and 27.3% of the E. coli and Klebsiella (K. pneumon- iae, K. ozytoca) isolated from other sterile body fluid were ESBLs-producing strains. Pan-resistant strains were identified in the A. baumannii (n = 10, 18.2%), K. pneumoniae (n = 8, 27.6 %) and P. aeruginosa (n = 1, 7.7%) isolates from cerebro- spinal fluid. Pan-resistant strains of A. baumannii (n= 43, 36.8%), K. pneumoniae (n = 18, 11.5%), P. aeruginosa (n = 3, 2.1%) and E. coli (n = 1, 0.2%) were isolated from other sterile body fluids. Conclusions The leading pathogenic bacteria isolated from cerebrospinal fluid and other sterile body fluid are E. coli, CNS, E. faecium, K. pneumoniae, A. baurnannii and P. aeruginosa. More attention should be paid to the threats caused by the pan-resistant Enterobacteriaceae, P. aeruginosa and A. baumannii.
出处 《中国感染与化疗杂志》 CAS 北大核心 2012年第4期259-267,共9页 Chinese Journal of Infection and Chemotherapy
关键词 细菌耐药性监测 无菌体液 细菌分布 药敏试验 bacterial resistance surveillance sterile body fluid bacterial distribution antimicrobial susceptibility testing
  • 相关文献

参考文献5

  • 1Clinical and Laboratory Standards Institute (CLSI). Perform ance standards for antimicrobial susceptibility testing [S]. M100-S20, 2010.
  • 2Thigpen MC, Whitney CG, Messonnier NE, et al . Bacterial meningitis in the United States, 1998-2007[J]. N Engl J Med, 2011, 364(21) :2016-2025.
  • 3Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carhapenemase producing bacteria[J].Lancet Infect Dis, 2009, 9(4): 228-226.
  • 4Higgins PG, Poirel L, Lehman M, et al. OXA -143, a novel carbapenem-hydrolyzing class D β-lactamase in Acinetobacter baumannii [J]. Antimicrob Agents Chemother, 2009, 53 (12) : 5035 5038.
  • 5Bogaerts P, Naas T, Garch FEI, et al. GES extended-spectrum β-lactamases in Acinetobacter baumannii isolates in Belgium[J]. Antimicrob Agents Chemother, 2010, 54 (11): 4872- 4878.

同被引文献103

  • 1朱德妹,胡付品,汪复,蒋晓飞,俞云松,杨青,孙自镛,简翠,王传清,王爱敏,张泓,李万华,徐英春,孙宏莉,倪语星,孙景勇,徐元宏,沈继录,胡云建,艾效曼,单斌,杜艳,魏莲花,吴玲,苏丹虹,卓超,贾蓓,黄文祥,张朝霞,季萍.2009年中国CHINET葡萄球菌属细菌耐药性监测[J].中国感染与化疗杂志,2010,10(6):414-420. 被引量:59
  • 2母丽媛,吕晓菊,马晓波,陈慧莉,陈文昭,过孝静,康梅.2300份成年人脑脊液培养及菌株耐药分析[J].中国抗生素杂志,2007,32(4):252-255. 被引量:17
  • 3李朝霞,刘又宁,王睿,童卫杭,程仕虎.左氧氟沙星联合万古霉素缩小金黄色葡萄球菌耐药突变选择窗的初步研究[J].中国临床药理学与治疗学,2007,12(8):911-914. 被引量:32
  • 4Karl D. The mutant selection window and antimicrobial resis- tance[J]. J Antimicrob Chemother, 2003, 52(1 ) : 11-17.
  • 5Rybak MJ. The pharmacokinetic and pharmacodynamic proper- ties of vancomycin[J]. Clin Infect Dis, 2006, 42 (Suppl 1 ): 35-39.
  • 6Clinical and Laboratory Standards Institute/NCCLS. Perfor- mance standards for antimicrobial susceptibility testing; twenti- eth informational supplement [J]. CLSI Document, 2010, 30 (1): 151-153.
  • 7European Committee on Antimicrobial Susceptibility Testing. breakpoint tables for interpretation of MICs and zone diameters. Version 2.0, valid from 2012-01-01.
  • 8Ruslami R, Nijland HM, Alisjahbana B, et al. Pharmacokinet- ics and tolerability of a higher rifampin dose versus the stan- dard dose in pulmonary tuberculosis patients[J]. Antimirob A- gents Chemother, 2007, 51(7): 2546-2551.
  • 9Chien SC, Rogge MC, Gisclon LG, et al. Pharmocokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses[J]. Antimirob Agents Chemother, 1997, 41 (10) : 2256-2260.
  • 10Udekwu KI, Parrish N, Ankomab P, et al. Functional rela- tionship between bacterial cell density and the efficacy of an- tibiotics[J].J Antimicrob Chemother, 2009, 63(4): 745-757.

引证文献9

二级引证文献66

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部